Funding Partners

Partners
>
Funding Partners

Funding Partners

CARB-X is a global non-profit partnership

CARB-X is funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the United States Department of Health and Human Services, Wellcome in the United Kingdom, Germany’s Federal Ministry of Education and Research (BMBF), the UK Government’s Department of Health and Social Care (DHSC), through its Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Bill & Melinda Gates Foundation, the world’s largest foundation dedicated to improving the quality of life for individuals around the world, and the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States’ National Institutes of Health (NIH).

Funders

Alliance Partners

United States’ Biomedical Advanced Research and Development Authority (BARDA)

BARDA is part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). BARDA draws on its extensive experience of successfully advancing promising medical countermeasures through late-stage development. BARDA provided CARB-X with $200 million from 2016-2022 with the potential of providing up to $300 million in additional support from 2022-2032.

Wellcome

Wellcome supports science to solve the urgent health challenges facing everyone. They support discovery research into life, health and wellbeing, and they’re taking on three worldwide health challenges: mental health, infectious disease and climate. Wellcome is one of the world’s leading funders of biomedical R&D, with significant experience and commitment in antibacterial R&D. Wellcome funded CARB-X with $155 million between 2016-2021 and committed up to $70 million from 2022-2024.

Germany’s Federal Ministry of Education and Research (BMBF)

Education and research are the foundations for our future. The promotion of education, science and research by BMBF represents an important contribution to securing Germany’s prosperity. Education and research are a German Federal Government policy priority, which is reflected in the development of the funding it is making available to these fields. BMBF funded CARB-X with €39 million (plus €1 million for the German Center for Infection Research) from 2019-2022, and has committed an additional €41 million to CARB-X and its Global Accelerator Network through 2026.

United States’ National Institute of Allergy and Infectious Diseases (NIAID)

NIAID is a US Government agency and is a key funder to protect against emerging infectious diseases, including antimicrobial resistance. NIAID commits in-kind services (e.g. preclinical services) to projects supported by CARB-X and retains key governance roles.

The United Kingdom’s Department of Health and Social Care (DHSC), Global Antimicrobial Resistance Innovation Fund (GAMRIF)

DHSC is the UK Government department which is responsible for helping people to live more independent, healthier lives for longer. The partnership with CARB-X is part of GAMRIF which was established to provide seed funding for innovative research and development in neglected and underinvested areas to address the threat of AMR in low- and middle-income countries. GAMRIF committed £21.1 million to CARB-X through 2022, and has committed an additional £24 million through March 2027.

Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation is a major funder of global health R&D. The foundation partners with CARB-X to advance the development of vaccines and novel biologics to avert drug-resistant diseases and protect the lives of vulnerable populations in low- and middle-income countries.

“The CARB-X initiative plays an important role in BARDA’s goal to catalyze the early stage development pipeline and enhance our national health security preparedness. CARB-X allows BARDA to tap into a partnership of co-funders, accelerators, and innovators who are pushing critical novel antimicrobials from discovery to the market to address the public health and national security concerns of antibiotic resistant bacteria.’’

— Gary L. Disbrow, Ph.D
BARDA Director